CBD for Psoriasis: The Immune Modulation Angle the Dermatology Community Is Watching

Psoriasis is one of the most researched conditions in the emerging field of endocannabinoid dermatology. The condition's well-characterized inflammatory mechanism -- driven by specific cytokines that are now the targets of the most expensive biologics in dermatology -- overlaps precisely with the cytokine pathways that CBD modulates through CB2 receptor activation. The dermatology community's interest in CBD for psoriasis is not peripheral -- it reflects the mechanistic logic of the ECS-psoriasis connection.

The Psoriasis Inflammatory Mechanism

Psoriasis is driven by a dysregulated immune response involving Th17 and Th1 immune cells that produce elevated levels of IL-17, IL-23, TNF-alpha, and IL-12. These cytokines activate keratinocytes to proliferate at a dramatically accelerated rate -- producing the thick, scaly plaques of psoriasis -- and maintain the chronic inflammatory environment that sustains the condition. The biologics that have revolutionized severe psoriasis treatment (secukinumab, ixekizumab, dupilumab) work by blocking specific cytokines in this pathway at significant cost and with systemic side effects.

Where CBD Intersects With Psoriasis Pathology

CB2 receptors are expressed on the Th17 and Th1 immune cells that drive psoriasis. CBD's CB2 activation reduces the cytokine production of these cells -- including IL-17 and TNF-alpha -- through the same general mechanism that biologics target, but locally rather than systemically and through receptor modulation rather than direct cytokine blockade.

Additionally, CB1 receptors in keratinocytes modulate cell proliferation. The accelerated keratinocyte proliferation that produces psoriatic plaques may be partially addressable through CB1-mediated antiproliferative signaling -- a mechanism that no conventional topical psoriasis treatment addresses.

The Current Research Landscape

Clinical research on topical CBD for psoriasis is early-stage compared to the eczema literature, but preliminary findings and the mechanistic rationale have generated significant interest. Case studies and small clinical observations suggest meaningful plaque reduction with consistent topical CBD application in some psoriasis subtypes. Larger randomized controlled trials are underway.

Restore as a Psoriasis-Appropriate Formula

Psoriatic skin is severely barrier-compromised and highly reactive to topical irritants. Restore's preservation-free, emulsifier-free, seed-oil-free wagyu tallow base minimizes topical inflammatory inputs while delivering CBD with maximum penetration through the oleic acid carrier effect. The CLA in the tallow base provides additional anti-inflammatory coverage. The formula is designed for the most sensitive, most inflamed skin -- exactly what psoriasis-affected skin represents.

Be among the first to experience Golden Tallow Restore. Join the early access list at early.goldentallow.com and explore the full Golden Tallow lineup at goldentallow.com. 🤍